Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US and Europe later this year.

Emboline has secured $20 million for its embolic protection system, designed to minimize stroke risk associated with transcatheter aortic valve replacement procedures. The Santa Cruz, CA-based company ...

CHICAGO, IL—Cerebral embolic protection devices are infrequently used during transcatheter aortic valve implantation procedures in the United States, and new data suggest their use does not appear to ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

(MENAFN- EIN Presswire) EINPresswire/ -- The Embolic Protection Devices Market is gaining significant traction globally, driven by the rising prevalence of cardiovascular diseases, increasing adoption ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

LONDON — Two years after the large multinational PROTECTED TAVR trial failed to associate a cerebral embolic protection (CEP) device with significant protection from stroke in patients undergoing ...

Please provide your email address to receive an email when new articles are posted on . Adults who underwent transcatheter aortic valve replacement with a cerebral protection system experienced fewer ...

Higher TAVI procedure volumes are associated with a greater likelihood of using an embolic protection device, data from more than 500 US hospitals show. The authors undertook the study expecting to ...

The "Embolic Protection Device Market Report, Forecast by Product, Application, Procedure, Material, Usage, End-User, Countries and Company Analysis, 2024-2032" report has been added to ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...